Oculus Innovative Sciences (OCLS) Misses Q2 EPS by 12c

Oculus Innovative Sciences (NASDAQ: OCLS) reported Q2 EPS of ($0.19), $0.12 worse than the analyst estimate of ($0.07). Revenue for the quarter came in at $3.8 million versus the consensus estimate of $3.56 million.

“We made a strategic decision in late 2014 to change our business model and enter the U.S. dermatology market directly. We deployed a direct U.S. sales force and over the last four quarters launched a total of six new prescription dermatology products. These efforts, combined with strong pricing reimbursement and rapid sales ramps, resulted in healthy sales growth during this quarter and over the last twelve months,” said Oculus CEO Jim Schutz. “We believe our growth in dermatology sales will continue as we launch new products, continue to ramp sales for our existing products lines and hire additional sales people.”

For earnings history and earnings-related data on Oculus Innovative Sciences (OCLS) click here.

You May Also Be Interested In

• Amphenol (APH) Tops Q1 EPS by 7c, offers guidance
• Capitol Federal Financial (CFFN) Misses Q2 EPS by 1c
• United Community Banks (UCBI) Tops Q1 EPS by 2c